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Background: Many biological factors of 2-[18 F]fluoro-2-deoxy-D-glucose (18 F-FDG) in blood can affect 18 F-FDG
uptake in tumors. In this study, longitudinal 18 F-FDG positron emission tomography (PET) studies were performed
on tumor-bearing mice to investigate the effect of blood glucose level and tumor size on 18 F-FDG uptake in
tumors.
Methods: Six- to eight-week-old severe combined immunodeficiency mice were implanted with glioblastoma U87
(n = 8) or adenocarcinoma MDA-MB-231 (MDA) (n = 11) in the shoulder. When the tumor diameter was
approximately 2.5 mm, a 60-min dynamic 18 F-FDG PET scan was performed weekly until the tumor diameter
reached 10 mm. Regions of interests were defined in major organs and tumor. A plasma curve was derived based
on a modeling method that utilizes the early heart time-activity curve and a late-time blood sample. The 18 F-FDG
uptake constant Ki was calculated using Patlak analysis on the tumors without an apparent necrotic center shown
in the PET images. For each tumor type, the measured Ki was corrected for partial volume (PV), and multivariate
regression analysis was performed to examine the effects of blood glucose level ([Glc]) and tumor growth.
Corrected Akaike's information criterion was used to determine the best model.
Results: The regression model that best fit the PV-corrected Ki for U87 data was Ki/RC = (1/[Glc]) × (0.27 ± 0.027)
mL/min/mL (where [Glc] is in mmol/L), and for MDA, it was Ki/RC = (0.04 ± 0.005) mL/min/mL, where Ki/RC denotes the
PV-corrected Ki using an individual recovery coefficient (RC). The results indicated that
18 F-FDG Ki/RC for U87 was
inversely related to [Glc], while [Glc] had no effect on 18 F-FDG Ki/RC of MDA. After the effects of PV and [Glc] were
accounted for, the data did not support any increase of 18 F-FDG Ki as the tumor (of either type) grew larger in size.
Conclusions: The effect of [Glc] on the tumor 18 F-FDG Ki was tumor-dependent. PV- and [Glc]-corrected
18 F-FDG Ki
did not show significant increase as the tumor of either type grew in size.
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Small-animal positron emission tomography (PET) im-
aging is being used increasingly in preclinical research. The
use of glucose analogue 2-[18 F]fluoro-2-deoxy-D-glucose
(18 F-FDG) for the in vivo measurement of local glucose
utilization rate in oncological animal models has been
a valuable tool for evaluation of treatment response.* Correspondence: HHuang@mednet.ucla.edu
1Department of Molecular and Medical Pharmacology, David Geffen School
of Medicine at UCLA, Rm. B2-085H CHS, 10833 Le Conte Avenue, Los
Angeles, CA 90095, USA
3Department of Biomathematics, David Geffen School of Medicine at UCLA,
Los Angeles, CA 90095, USA
Full list of author information is available at the end of the article
© 2013 Sha et al.; licensee Springer. This is an O
Attribution License (http://creativecommons.or
in any medium, provided the original work is pLongitudinal imaging allows tracking of the disease pro-
gression and provides more sensitive qualitative and quan-
titative assessments of the effects of an intervention than
non-longitudinal measurements [1,2]. Reduction in
18 F-FDG uptake from its baseline value is usually used as
an indicator of the tumor response to treatment. Standard
uptake value (SUV) [3] is commonly used as a measure of
glucose utilization activity, but it can be influenced by a var-
iety of biologic and technical factors, including the plasma
time-activity curve and blood glucose level [4]. The effect of
blood glucose level on 18 F-FDG uptake in tumors has been
investigated before but with conflicting results. Some found
benefit in normalizing SUV by blood glucose level [5-7];pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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indicated that 18 F-FDG uptake in various tissues is affected
by blood glucose level differently [11]. It is likely that the
value of SUVmay not necessarily reflect directly the glucose
utilization rate in the tissue of concern, and adjustments for
glucose level should not be done indiscriminately.
In this work, we addressed the effect of blood glucose
level and tumor growth on both the SUV and 18 F-FDG
uptake constant (Ki) in two different types of tumors.
The input function for the calculation of 18 F-FDG Ki
was derived based on a modeling method that utilizes
the early-time dynamic PET images of the heart cham-
ber and a single blood sample taken at the end of the
scan [12]; so, the experimental animal did not need to
be sacrificed after each scan, and multiple longitudinal
studies could be performed. The use of an input
function for quantitation of biological function seeks to
reduce many effects due to systemic variations.Methods
Tumor models and small-animal imaging
Nineteen 6- to 8-week-old severe combined immunode-
ficiency (SCID) mice were maintained in a strict defined-
flora, pathogen-free environment in the AAALAC-
accredited animal facilities at UCLA. Human glioblastoma
cell line U87 and breast cancer cell line MDA-MB-231
(MDA) were used as a SCID-hu tumor model. Tumor
cells were injected (with MDA cells in 11 mice and with
U87 cells in 8) subcutaneously as single-cell suspensions
in phosphate buffer saline (PBS; about 2 × 106 MDA or
about 6 × 105 U87 cells in 100 μL PBS). When the diam-
eter of the tumor grew to approximately 2.5 mm, a PET
scan was performed once a week on the same animal until
the diameter of the tumor exceeded 10 mm. Tumor size
was measured weekly with a caliper, and the volume was
calculated as 0.5 × length × width2.
Small-animal PET scans were performed either on a
microPET Focus 220 scanner running microPET Manager
2.4.1.1 or on an Inveon dedicated PET running IAW 1.5
(Siemens Preclinical Solutions, Knoxville, TN, USA), but
the same scanner was used for multiple longitudinal PET
scans of each mouse. These scanners provide the same
SUV and % ID values for mice imaged sequentially in both
systems (unpublished data). List-mode PET data were ac-
quired for 60 min immediately after 18 F-FDG injection
via a tail vein catheter (18.28 ± 1.19 MBq, approximately
60 μL) in a bolus. Frame durations of all the PET studies
were 4 × 1 s, 15 × 0.5 s, 1 × 2 s, 1 × 4 s, 1 × 6 s, 1 × 15 s,
3 × 30 s, 1 × 60 s, 1 × 120 s, 3 × 180 s, 3 × 900 s, and 1 ×
51 s. After the PET scan was completed, a 10-min CT scan
was acquired with a small-animal CT scanner (MicroCAT
II, Siemens Preclinical Solutions, Knoxville, TN, USA) for
attenuation correction of the PET measurements.Tail vein blood glucose levels (in mmol/L) were mea-
sured using a blood glucose meter (Abbott AlphaTRAK,
Abbott Laboratories, Abbott Park, IL, USA) at the begin-
ning and the end of each scan. A single blood sample
(approximately 10 to 15 μL) was collected with a 1-cc syr-
inge from the heart at the end of the study (approximately
70 to 80 min). The whole blood in the syringe was
released to a pre-weighed test tube and weighed, and the
radioactivity was counted in a gamma counter (WIZARD
3"; PerkinElmer Life Sciences, Turku, Finland).
All animal experiments were performed in accordance
with institutional guidelines and protocols approved by
the Animal Research Committee of the University of
California, Los Angeles, USA.
Image analysis
Image analysis was performed using AMIDE (http://amide.
sourceforge.net/). The 3D isocontour regions of interest
(ROIs) were manually defined for the skeletal muscle of the
left ventricle (LV), forelegs, liver, and tumor in each mouse
on the last 15-min images (about 60 min post 18 F-FDG in-
jection). Only tumors without an apparent necrotic center
on the 18 F-FDG PET images were included in the analysis.
The time-activity curves (TAC) in each tissue of interest
were calculated. Experimental information for all studies is
available online at the UCLA Mouse Quantitation Project
website (http://dragon.nuc.ucla.edu/mqp/index.html).
For semi-quantitative analysis, SUV was calculated using
the mean voxel value within the ROI of the last 15-min
frame (Equation 1). SUVs of each study were recorded
and were used for generating the TACs.
SUV ¼ Radioactivity concentration in ROI MBq=mLð Þ
Injected dose MBqð Þ=Weight of the animal gð Þ
ð1Þ
Plasma input function
The plasma TAC (TACp; the input function) was derived
based on the method reported by Ferl et al. [12]. The
method included the use of the early-time LV TAC
(t < 1 min) (with corrections of delay, dispersion, partial
volume effects, and red blood cell uptake) and one whole
blood sample taken at the end of the study (approximately
70min). For each study, a time-dependent plasma-to-whole
blood 18 F-FDG equilibrium ratio, RPB(t) (Equation 2), was
used to convert the whole blood 18 F-FDG concentrations
to those in plasma [11].
RPB tð Þ ¼ 0:386e−0:191t þ 1:165; ð2Þ
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input function was assumed to be describable with four
exponential components (Equation 3):
TACp ¼ A1eμ1 t þ A2eμ2 t þ A3eμ3 t
 A1 þ A2 þ A3ð Þeμ4 t : ð3Þ
The sum of the first three exponential terms was used
to describe the main part of the input function; the
fourth exponential term was needed so that TACp was
equal to 0 at time 0. All parameters were estimated by
simultaneously fitting the plasma 18 F-FDG blood curve
with Equation 3 and the muscle and liver TACs with
two separate 4 K compartmental 18 F-FDG models as de-
scribed by Ferl et al. [12]. The kinetic modeling program
SAAM II [13] was used to solve the systems of differen-
tial equations and estimate parameters. The Bayesian
maximum a posteriori parameter estimation in SAAM II
was used to improve parameter identification and the
accuracy of the predicted input function as described by
Ferl et al. [12].
Kinetic analysis
Both the PET image and blood data were converted to
absolute radioactivity concentration (Bq/mL) using a cross-
calibration factor derived from cylinder phantom experi-
ments. The 18 F-FDG uptake rate constant Ki (Ki =K1k3/
(k2 + k3)) was estimated via the Patlak graphical analysis
[14] using the derived plasma input function and tumor
TAC data by taking the slope of the linear portion from
15 to 60 min of the plot based on Equation 4:
CT tð Þ










CP tð Þ þ
V BCB tð Þ
CP tð Þ ; ð5Þ
where CT(t) is the total
18 F-FDG concentration in the
tissue of interest, C1(t) is the free
18 F-FDG concentra-
tion in the tissue, Cp(t) is the
18 F-FDG concentration in
the plasma, CB(t) is the blood
18 F-FDG concentration
in the vasculature, and VB is the volume fraction of
blood in the tissue. The early-time tissue data (for t <
15 min) were not used because only after an equilibra-
tion time (t*) will the Patlak plot become linear. The
metabolic rate of glucose (MRGlu) was calculated as
MRGlu = Ki × [Glc]/LC [15], where [Glc] was the aver-
aged blood glucose level of the two measurements at
the beginning and the end of the scan, and LC is the
lumped constant. Values of the LC were assumed to be
1.4 for U87 [16] and 1.0 for MDA. The intercept value
(Int) shown in Equation 5 is related to the VB and the
distribution volume of the tracer in the reversible tissue
compartment.Data analysis and functional relationship determination
Ki and SUVs were partial volume (PV)-corrected by
dividing the values by the recovery coefficient (RC) of
the tumor. As a first-order approximation, RC for a
tumor was calculated based on a sphere of diameter =ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




;the spatial resolution of the microPET
scanner, and an assumed background activity level of
10% of the activity level in the sphere. Four models
(Equations 6 to 9) were tested to fit the relationship of
glucose concentration and tumor diameter to quantita-
tive PET measures, Y (SUV/RC or Ki/RC).
Y ¼ a: ð6Þ
Y ¼ aþ c tumor diameter½ : ð7Þ
Y ¼ a
bþ Glc½  ð8Þ
Y ¼ aþ c tumor diameter½ ð Þ
bþ Glc½  ð9Þ
The parameters a and c were to account for the effect
due to tumor growth in size; b was equivalent to the half
saturation glucose concentration of 18 F-FDG uptake
[11]. Models were tested separately for U87 and MDA.
To account for possible effects introduced through re-
peated measures, models were fit using standard least-
squares method as well as mixed-effects method [17].
For models 3 and 4 (Equations 8 and 9), if fitted values
for parameter b were not found to be significant, the
model was rebuilt, setting b equal to 0. Mixed-effects
models were built assuming no within-group covariance
of random effects. For models with more than one fitted
parameter, all possible combinations of random effects
were tested. If more than one mixed-effect model
showed significant improvement over the standard
fixed-effect model, the optimal mixed-effect model was
chosen by the likelihood ratio test if models were nested
or by the corrected Akaike's information criterion
(AICc), otherwise. After a fitting method for each model
was chosen, the optimal model for each cell line and re-
sponse variable was chosen based on AICc. Fittings and
model comparison were done using the nlme package of
the statistical software R [18].
Results
Examples of the coronal tomographic images of weekly
microPET scans of a mouse implanted with MDA or U87
tumor cells are shown in Figure 1. The tumors were barely
detectable on microPET images by days 28 and 37 after
implantation for U87 and MDA, respectively. For MDA
tumors, with 33 imaging studies in total, a necrotic core
was observed in 17 cases as early as the tumor diameter
reached 5 mm, while for U87, with 27 imaging studies in
Figure 1 Longitudinal 18 F-FDG PET images of a mouse. With (A) U87 and (B) MDA-MB-231 implanted in the shoulder region. In the graphs,
day 1 is the date when the first PET scan was performed.
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tumor diameters >8 mm. At the beginning time of each
PET scan, the averaged blood glucose levels were 6.88 ±
2.52 and 7.79 ± 2.52 mmol/L, respectively, for MDA-
and U87-bearing mice. A modest increase of the [Glc]
value was observed at the end of the scan (MDA 8.19 ±
2.25 mmol/L, U87 8.45 ± 2.37 mmol/L), probably due to
the effect of isoflurane anesthesia [19].
Tumor size
The tumor volume and calculated diameter, respectively,
at the time of the first PET scan were 6.06 ± 2.45 mm3
and 2.26 ± 0.33 mm for the MDA group and 5.88 ±
2.64 mm3 and 2.23 ± 0.34 mm for the U87 group. Tumor
volumes continued to increase over time as shown in
Figure 2. Tumor diameter appeared to grow linearly with
time (Figure 2B). There was no significant difference
(P > 0.05) in tumor growth rate between the two tumor
types (Figure 2). The largest difference between the tumor
sizes of the two tumors was at about 30 days after the first
PET scan, but the difference was not significant (P > 0.05).
Tumor 18 F-FDG uptake and metabolic parameters
Partial volume effect (PVE) of 18 F-FDG uptake in tumors
with a necrotic core was more difficult to account for
since the tumor 18 F-FDG uptake became heterogeneous
after the necrotic core development. For evaluation of the
effects of blood glucose level and tumor growth, onlyscans without tumor necrotic cores were investigated in
this work. SUV was used for semi-quantitative analysis
and model fitting to estimate the model parameter values.
SUV was found to significantly correlate with the Patlak
analysis-derived Ki (P < 0.001 for both tumors) and with
MRGlu (P < 0.001 for both tumors).
The relationships as a function of tumor diameter for
tumor SUV, Ki, and MRGlu are shown in Figure 3 for
MDA and U87 tumors. Linear regression analysis was
made based on the data pooled from studies with non-
necrotic tumors. There was a significant positive correl-
ation between SUV, Ki, or MRGlu, and tumor size for U87
(SUV R2 = 0.57, P < 0.001; Ki R
2 = 0.24, P = 0.027; MRGlu
R2 = 0.22, P = 0.039), while no significant corresponding
correlations were found for MDA (SUV R2 = 0.15, P =
0.13; Ki R
2 = 0.035, P = 0.49; MRGlu R2 = 0.017, P = 0.63).
For the blood glucose effect on SUV, Ki, and MRGlu
(Figure 4), neither tumor SUV nor Ki was found to be cor-
related with the blood glucose level for MDA (with both
slope of regression lines and R2 not significantly different
from 0, P > 0.05). However, for U87, there was a modest
dependency (P < 0.05 for both SUV and Ki) on blood glu-
cose levels. MDA MRGlu was positively correlated with
blood glucose levels (R2 = 0.39, P = 0.009), while no signifi-
cant correlation was found between MRGlu and blood
glucose levels for U87 (P > 0.05).
The Patlak analysis also showed that U87 tumors had
on average a larger Int (Equation 5) value (0.50 ± 0.13
Figure 2 Tumor volume measurements and calculated
diameter throughout the experiment. The (A) tumor volume
measurements and (B) calculated diameter are for MDA-MB-231 and
U87 mice. Day 1 is the date when the first PET scan was performed.
Error bars represent 1 SD.
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reflects the fractional blood volume VB and the distri-
bution volume of the tracer in the reversible tissue
compartment (Equation 5), the higher Int value of U87
signified higher vascular volume and larger K1 of
18 F-
FDG in U87, a possible indication of more angiogenesis,
than in MDA tumors.
PV-corrected 18 F-FDG uptake versus blood glucose level
and tumor size
The RC calculated for PV correction ranged from 0.34 to
0.93 when the sphere radius was from 0.5 to 10 mm. PV-
corrected SUV and 18 F-FDG Ki in the tumor were fitted
by the functions of Equations 6 to 9. Results of model fit-
tings and model comparison are shown in Tables 1 and 2.
All of the models are derived from the mouse studyshowing a tumor with a diameter of >2.5 mm. In the case
of U87, for all models and both response variables (i.e.,
SUV and Ki), mixed-effects modeling did not have a sig-
nificant improvement over standard fitting (Table 1),
where residual sum of squares (RSS) and AICc are calcu-
lated based on the non-mixed-effects models. Likelihood
ratio tests in Table 1 represent the mixed-effect model
with the smallest P value. Additionally, for both response
variables, models 3 and 4 (Equations 8 and 9) did not re-
turn significant values for the parameter b in either fixed-
or mixed-effects models. Therefore, data in Table 1 repre-
sent models built with b set to 0. For both response vari-
ables, model 3 was ranked as optimal based on AICc.
In the case of MDA (Table 2), for both response vari-
ables, mixed-effects modeling showed a significant im-
provement over standard fitting in models 1 (Equation 6)
and 2 (Equation 7). RSS and AICc were thus calculated
based on the mixed-effects models. For models 3 and 4,
they were based on the non-mixed-effects models because
incorporation of mixed effects did not lead to a significant
improvement over standard fitting. For both response
variables, model 1 was ranked as optimal based on AICc.
For the MDA cell lines, the best models were SUV/RC =
1.8 ± 0.15 (P < 10−5), with random effect SD = 0.414, andKi/
RC = 0.04 ± 0.005 mL/min/mL (P < 10−5), with random
effect SD = 0.014. For the U87 cell lines, the best models
were SUV/RC = (1/[Glc]) × (14.36 ± 0.85), (P < 10−5), and
Ki/RC = (1/[Glc]) × (0.27 ± 0.027) mL/min/mL, (P < 10
−5).
After both partial volume and blood glucose concentration
were accounted for (MDA: corrected SUV = SUV/RC
and corrected Ki =Ki/RC; U87: corrected SUV = (SUV ×
[Glc])/RC and corrected Ki = (Ki × [Glc])/RC), the data did
not support any significant change of SUV or Ki when the
tumor (of either cell line) grew bigger in size (but before
necrotic core development) as shown in Figures 5 and 6
(corrected SUV: R2 = 0.14 and 0.0009 for MDA and U87,
respectively; corrected Ki: R
2 = 0.09 and 0.02 for MDA and
U87, respectively, P > 0.05 for all situations). The corrected
SUV or corrected Ki was also found to be uncorrelated to
blood glucose concentrations with the slope of regression
lines not significantly different from 0 (corrected SUV:
R2 = 0.0006 and 0.04 for MDA and U87, respectively;
corrected Ki: R
2 = 0.03 and 0.003 for MDA and U87,
respectively, P > 0.05 for all situations).
Discussion
In this work, a set of longitudinal quantitative 18 F-FDG
PET studies was performed on tumor-bearing mice, and
a method to account simultaneously for the blood glu-
cose level and tumor growth has been tested. While the
impact of medium/blood glucose levels on 18 F-FDG up-
take in tumors has previously been investigated in both
in vitro and in vivo studies [20,21], no longitudinal stu-
dies have been reported to elucidate the associations of
Figure 3 Relationships versus tumor diameter for SUV, Ki, and MRGlu. (A) MDA-MB-231 (top row). (B) U87 (bottom row).
Figure 4 Relationships versus blood glucose level for SUV, Ki, and MRGlu. (A) MDA-MB-231 (top row). (B) U87 (bottom row).
Sha et al. EJNMMI Research 2013, 3:51 Page 6 of 11
http://www.ejnmmires.com/content/3/1/51
Table 1 Likelihood ratio test on analysis methods and model selection for U87
Response variable Modela Log likelihood Random
parameters
Dd Pd AICc RSS
Standardc Mixedc
Ki/RC 1 54.81 54.81 a 1.4 × 10
−8 >0.99 −105.41 4.88 × 10−3
2 55.00 54.82 a, c 0.368 0.947 −102.92 4.87 × 10−3
3b 55.91 55.91 a 1.03 × 10−8 >0.99 −107.12 4.36 × 10−3
4b 56.14 56.14 a 1.03 × 10−8 >0.99 −102.78 4.27 × 10−3
SUV/RC 1 −15.45 −15.45 a 4.3 × 10−9 >0.99 35.12 5.49
2 −15.29 −14.53 a, c 1.53 0.675 37.29 5.41
3b −13.10 −13.04 a 0.102 0.75 30.41 4.34
4b −13.07 −13.04 a 0.0606 0.81 32.85 4.33
aModels 1 to 4 correspond to Equations 6 to 9. bThese models were built with b set to 0. cStandard denotes the standard least-squares method, and mixed
denotes the mixed-effects method. dD is the likelihood ratio statistic, and P is the significance level.
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Ki in tumors. Our quantitative analysis based on
18 F-
FDG uptake, kinetics analysis, and model selection ad-
dresses the effect of blood glucose level and tumor size
(for tumors without necrotic cores) in two different
types of tumors. The results suggested that the need to
account for the confounding effects of glucose in the fit-
ting of measured data is tumor cell line dependent and
that appropriately taking this into account would lead to
improvement in the measurement sensitivity of the true
biological signals in the tumors.
Results of the growth rate and Patlak analysis showed
that human breast cancer MDA cells have an adequate
proliferation rate in SCID mice for longitudinal 18 F-
FDG PET studies, as do human glioma U87 cells. In this
work, tumor growth was monitored longitudinally, and
it was found that MDA and U87 had a similar growth
rate for about 30 days after the baseline imaging time
point (Figure 2). However, MDA developed necrotic
cores much earlier than U87 (Figure 1), probably due to
different angiogenesis rates between the two tumor types
(U87 >MDA). The larger Int value derived from the U87
tumor 18 F-FDG kinetics is consistent with having moreTable 2 Likelihood ratio test on analysis methods and model
Response variable Modela Log likelihood R
paStandardb Mixedb








aModels 1 to 4 correspond to Equations 6 to 9. bStandard denotes the standard lea
likelihood ratio statistic, and P is the significance level.angiogenesis in U87. Although a larger proportion of
tumor cells in tissue would increase the FDG uptake rate
constant and thus the slope of the Patlak plot, it is not
expected to affect the value of Int by a large amount.
The larger value of Int also supports the reasoning that
the higher angiogenesis rate is the cause of the observed
slower development of necrotic core in the U87 tumors
as compared to the MDA tumors.
In PET tumor imaging, SUV is the most frequently used
index for characterizing tumor 18 F-FDG uptake. However,
the value of its use for interpreting 18 F-FDG PETscans was
found to be limited because of the considerable overlap be-
tween SUV measurements in malignant and benign lesions
and subtle changes at early response to therapy [22]. There-
fore, large variability in SUVmeasurements could affect the
clinical interpretation. Generally speaking, these variability
sources can be categorized into two types. One comes from
biological factors (e.g., tumor's size/configuration changes,
plasma substrate level, insulin level, and input function
variations). Another type is associated with technical fac-
tors (e.g., reconstruction parameter changes). Our study
was designed to examine the effect of blood glucose level
and tumor growth on 18 F-FDG uptake.selection for MDA
andom
rameters
Dc Pc AICc RSS
a 7.16 0.0075 −90.9 1.46 × 10−4
a 7.06 0.0079 −88.64 1.31 × 10−4
a, b 2.58 × 10−5 >0.99 −56.46 0.0178
a, b 2.29 × 10−9 >0.99 −55.67 0.015
A 3.95 0.047 26.48 0.591
a, c 8.02 0.0456 28.73 0.129
a 2.54 × 10−5 >0.99 69.42 46.57
a 7.07 × 10−6 >0.99 66.56 32.14
st-squares method, and mixed denotes the mixed-effects method. cD is the
Figure 5 Relationships of corrected SUV versus tumor size and blood glucose level. Top row, MDA-MB-231; bottom row, U87.
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relatively constant when the tumor grew bigger (Figure 3);
no correlation was found between SUV or Ki, and blood
glucose levels, but MRGlu increased with increasing blood
glucose levels (Figure 4). Unlike that in MDA, SUV and Ki
in the U87 tumor correlate significantly with tumor size
and blood glucose levels, indicating that correction for
both blood glucose level and tumor size is needed in the
calculation of SUV and Ki to reflect tumor glucose
utilization rate. These results also suggested that the glu-
cose uptake regulation could be different in different
tumor types, and correcting for blood glucose level or not
in the SUV formula should be done selectively. Reported
results in the literature on the effect of blood glucose
levels on a few other types of tumors were somewhat con-
troversial. Most studies have demonstrated that 18 F-FDG
uptake into human cancer cells is inhibited by increasing
blood glucose levels because of saturation of glucose
uptake in tumors [6,7]. Our results from U87 data were
consistent with these findings. However, animal studies
performed by Torizuka et al. [10] indicated that the up-
take of 18 F-FDG in mammary carcinoma was reduced for
insulin-induced hypoglycemia. In our present study, 18 F-FDG SUV in the mammary cancer MDA has a slightly
negative slope but with an insignificant correlation, with
respect to blood glucose levels (Figure 4).
When tracer uptake in small tumors was measured,
large biases could be introduced by the PVE [23]. We
used the calculated RC to reduce the errors attributable
to PVE. Four models (Equations 6 to 9) with one to
three independent parameters were used to account for
glucose level and to evaluate if the PV-corrected 18 F-
FDG SUV and Ki changed as the tumors grew in size.
Likelihood ratio tests (Tables 1 and 2) showed that
mixed-effects modeling is not necessary for the U87 data
but is necessary for the MDA cell line, suggesting that
the U87 has more homogenous development than the
MDA among different mice. This is consistent with the
larger data scatter of 18 F-FDG uptake obtained for the
MDA cell line than for U87 in in vitro experiments
using multiwell plates [24]. The best model (Equation 8)
for U87 indicates that U87 Ki was inversely correlated to
the blood glucose levels. That is similar to our previous
findings on 18 F-FDG Ki in the brain [11] that showed a
significant inverse relationship between cerebral 18 F-
FDG Ki and the blood glucose level. The best model
Figure 6 Relationships of corrected Ki versus tumor size and blood glucose level. Top row, MDA-MB-231; bottom row, U87.
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our in vitro studies, which showed that the 18 F-FDG up-
take in MDA was affected little by medium glucose level
over the normal physiological glucose range [24]. Since
U87 is a human cancer cell line originating from the
brain, the finding that U87 behaves like the brain tissue
in glucose metabolism is interesting, but not unexpected.
The 18 F-FDG SUV and Ki, after accounting for the PVE
and blood glucose levels (Figures 5 and 6), did not show
any significant correlation with tumor size, further
confirming that tumor glucose utilization rate was rather
stable when the tumor (of either MDA or U87) grew big-
ger in size (but before necrotic core development). The re-
lationship indicates that without treatment intervention,
tumor cells/tissues do not change their metabolic aggres-
siveness as tumors grow (at least before necrosis appears).
The current results showed that the use of either SUV or
Ki gave the same conclusion regarding the effects of blood
glucose level and tumor growth on glucose utilization rates
for MDA and U87. The use of Ki, however, was supposed to
better account for the systemic variations in 18 F-FDG deliv-
ery between studies or animals. In the present study, these
variations were small because the animals were obtainedfrom the same source, had the same diet and similar age,
and were treated similarly. When the variations in the sys-
temic condition are large, as in a patient population, the use
of SUV as an indicator of tumor glucose utilization rate is
expected to give a larger variability than that of Ki and may
not be as sensitive to reveal the same effects. Similar advan-
tages ofKi over SUVwere also observed in one of our previ-
ous studies on the effects of blood glucose level on the brain
18 F-FDG uptake [11]. The main desirable feature of SUV is
that it does not need dynamic PET imaging and is thus
more practical for human studies.
The present results indicate that 18 F-FDG Ki in MDA
and U87 differs considerably in response to altered blood
glucose level, suggesting that regulation of 18 F-FDG up-
take and glucose metabolism are tumor-type dependent.
However, more work needs to be done to account for ef-
fects due to other possible factors, including blood insulin
level and tumor heterogeneity (when a necrotic core ap-
pears), to further improve the reliability of the quantitative
measurements and to examine the metabolic stability/
change after a necrotic core develops. Insulin is known to
induce a host of effects on traditional metabolic actions
such as glucose transport and utilization [25]. Insulin also
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tissues [26]. Although the effects of insulin on tumor 18 F-
FDG uptake have been studied by others before [10,27],
the prior studies all involved insulin injections into the
animal or patient that yielded a non-steady state circulat-
ing insulin level and also a variable blood glucose level at
the same time. As a result, 18 F-FDG uptake could be
affected by either or both factors and is more difficult to
interpret. Only after the known confounding factors are
properly accounted for can one begin to critically assess
the temporal changes in 18 F-FDG uptake kinetics during
normal growth or due to intervention or treatment.
A frequently asked question about 18 F-FDG uptake in
tumors is whether it reflects more tumor biology versus
inflammatory response associated with the xenograft.
Our present study would not be able to provide a defini-
tive answer. Although inflammatory response is usually
considered to be transient, it could be compensated by
tumor biology changes. A longitudinal PET study with co-
ordinated tissue autopsy examination could be performed
in the future to address this question.
Conclusions
Results from the present study showed that 18 F-FDG Ki in
the U87 tumor varies inversely with the blood glucose
levels. In contrast, MDA 18 F-FDG Ki is independent of the
blood glucose level, indicating that different transporter/
hexokinase adaptations to blood glucose levels exist for the
two tumor types. Thus, adjustment of tumor 18 F-FDG
uptake for blood glucose level should be applied only for
tumor types that have their 18 F-FDG uptake sensitive to
blood glucose levels. Moreover, partial volume and glucose-
corrected 18 F-FDG Ki did not show any significant increase
as the tumor of either type grew in size.
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